US Marijuana Research is Witnessing an Evolving Landscape
The nascent cannabis research field recently hit a major milestone after the U.S. Food & Drug Administration (FDA) finally greenlit Phase 2 of the Multidisciplinary Association for Psychedelic Studies (MAPS) study on the feasibility of using smoked cannabis to treat post-traumatic stress disorder (PTSD) in veterans. The authorization came after three years of discussion between the FDA and MAPS. Titled MJP2, the study will test the efficacy and safety of inhaling high-THC cannabis in managing PTSD symptoms in veterans compared to a placebo. Nearly 320 veterans from Michigan and three additional states will take part in the study. The Michigan…

















